Shopping Cart
Remove All
Your shopping cart is currently empty
Degarelix
Copy Product Info
😃Good
Catalog No. T10988Cas No. 214766-78-6
Alias FE200486 free base, FE 200486 free base
Degarelix is a peptide and selective GnRH (human gonadotropin-releasing hormone) receptor antagonist that treats prostate cancer by lowering testosterone levels in the body.
Degarelix
Copy Product Info😃Good
Purity: 99.34%
Catalog No. T10988Alias FE200486 free base, FE 200486 free baseCas No. 214766-78-6
Degarelix is a peptide and selective GnRH (human gonadotropin-releasing hormone) receptor antagonist that treats prostate cancer by lowering testosterone levels in the body.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $185 | - | In Stock | |
| 5 mg | $516 | - | In Stock | |
| 10 mg | $825 | - | In Stock | |
| 25 mg | $1,438 | 7-10 days | 7-10 days | |
| 50 mg | Inquiry | 7-10 days | 7-10 days |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.34%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Degarelix is a peptide and selective GnRH (human gonadotropin-releasing hormone) receptor antagonist that treats prostate cancer by lowering testosterone levels in the body. |
| In vitro | Degarelix significantly reduced cell viability in multiple prostate-derived cell lines (1 nM–10 μM, 0–72 h), with no inhibitory effect on PC-3 cells[1].Degarelix suppressed prostate cell growth by inducing apoptosis (10 μM, 0–72 h)[1]. |
| In vivo | In rats, a single subcutaneous dose of Degarelix (1–10 mg/kg, sc) caused dose-dependent testosterone suppression lasting >30 days[1].In prostate cancer patients, Degarelix (240 mg loading dose followed by monthly 80 mg sc) rapidly reduced serum testosterone to castrate levels (≤0.5 ng/mL), without the agonist-related hormone surge, and maintained suppression for at least 1 month[1]. |
| Synonyms | FE200486 free base, FE 200486 free base |
| Molecular Weight | 1632.26 |
| Formula | C82H103ClN18O16 |
| Cas No. | 214766-78-6 |
| Smiles | C([C@@H](NC([C@@H](NC([C@@H](CC1=CC=C(NC(N)=O)C=C1)NC([C@H](CC2=CC=C(NC(=O)[C@@H]3CC(=O)NC(=O)N3)C=C2)NC([C@@H](NC([C@@H](CC=4C=CC=NC4)NC([C@@H](CC5=CC=C(Cl)C=C5)NC([C@@H](CC6=CC7=C(C=C6)C=CC=C7)NC(C)=O)=O)=O)=O)CO)=O)=O)=O)CC(C)C)=O)CCCCNC(C)C)(=O)N8[C@H](C(N[C@@H](C(N)=O)C)=O)CCC8 |
| Relative Density. | 1.325 g/cm3 (Predicted) |
| Sequence | Ac-D-2Nal-D-Phe(4-Cl)-D-3Pal-Ser-Phe(4-S-dihydroorotamido)-D-Phe(4-ureido)-Leu-Lys(iPr)-Pro-D-Ala-NH2 |
| Sequence Short | XXXSXXLXPA |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||
| Solubility Information | H2O: 4 mg/mL (2.45 mM), Sonication is recommended. DMSO: 8 mg/mL (4.9 mM), Sonication is recommended. | ||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (0.61 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||
Solution Preparation Table | |||||||||||
H2O/DMSO
| |||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Degarelix | purchase Degarelix | Degarelix cost | order Degarelix | Degarelix chemical structure | Degarelix in vivo | Degarelix in vitro | Degarelix formula | Degarelix molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.